A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects.

Trial Profile

A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Jul 2016

At a glance

  • Drugs Tivozanib (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms BATON-CRC
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 11 Jul 2016 Results (n=265) published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 04 Jul 2015 Results presented at the 17th World Congress on Gastrointestinal Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top